India recommends compulsory licence for anti-cancer drug

12-09-2013

India recommends compulsory licence for anti-cancer drug

The Health Ministry in India has recommended that a compulsory licence (CL) is issued for the manufacture of Bristol-Myers Squibb’s (BMS) anti-cancer drug Sprycel (dasatinib), potentially opening the door to the sale of cheaper imitations.  


Dasatinib, Sprycel, IP, patents, WTO TRIPS, India, DIPP,

LSIPR